v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues REVENUES:
Revenues by Product Line. The following table represents total net revenues by product line:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
HIV$14,170 $14,398 $27,189 $27,298 
Sample Management Solutions (1)
9,875 9,855 18,933 18,965 
HCV3,393 4,126 6,056 8,459 
Other product and services revenues (2)
2,285 994 3,903 1,767 
COVID-19 (3)
1 28 19 489 
Risk Assessment Testing (4)
— 446 — 1,866 
Net product and services revenues$29,724 $29,847 $56,100 $58,844 
Non-product and services revenues (5)
915 1,395 2,464 2,329 
Net revenues$30,639 $31,242 $58,564 $61,173 
(1) Includes Genomics, Microbiome and Colli-Pee® product revenues.
(2) Includes Syphilis revenues and single order fulfillment.
(3) Includes COVID-19 Diagnostics and COVID-19 Sample Management Solutions revenues.
(4) Includes substance abuse testing product revenues.
(5) Includes funded research and development contracts, royalty income and grant revenues.
Revenues by Geographic Area. The following table represents total net revenues by geographic area, based on the location of the customer:
For the Three Months Ended June 30,For the Six Months Ended June 30,
2026202520262025
United States$20,235 $19,852 $38,907 $40,187 
Africa6,786 8,027 13,560 15,216 
Europe1,743 2,117 3,192 3,754 
Other regions1,875 1,246 2,905 2,016 
$30,639 $31,242 $58,564 $61,173 
Customer Concentrations. The following table represents customer concentration risk:
June 30,December 31,
Accounts Receivable20262025
Commercial customer (1)
14 %N/A
Commercial customer (1)
11 %15 %
(1) Each commercial customer is a different international distributor.
Vendor Concentrations. The Company currently purchases certain products and critical components of the Company's products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of the Company's products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on the Company's business, as well as the Company's financial condition and results of operations.
Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2026 and December 31, 2025 was comprised of customer prepayments of $0.9 million and $1.2 million, respectively. Deferred revenue as of December 31, 2025 was also comprised of $0.4 million of unearned grant income. The Company had no unearned grant income in deferred revenue as of June 30, 2026.
The following table represents deferred revenue recognized:
For the Three Months Ended June 30,For the Six Months Ended June 30,
Deferred Revenue Recognized2026202520262025
Accrued at beginning of year$148 $974 $1,109 $1,461